Supernus Pharmaceuticals (NASDAQ:SUPN) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note published on Monday morning, MarketBeat.com reports. The firm issued an overweight rating and a $57.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $38.06 on Monday. The stock’s fifty day moving average price is $36.34 and its 200 day moving average price is $33.15. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $39.37. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 35.57 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period last year, the business posted ($0.29) earnings per share. Research analysts expect that Supernus Pharmaceuticals will post 2.37 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 154,213 shares of company stock worth $5,660,180. Corporate insiders own 9.30% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of large investors have recently bought and sold shares of SUPN. Armistice Capital LLC raised its stake in shares of Supernus Pharmaceuticals by 47.6% during the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after buying an additional 1,700,000 shares during the period. Dimensional Fund Advisors LP increased its holdings in Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after acquiring an additional 309,966 shares in the last quarter. Stephens Investment Management Group LLC raised its position in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after acquiring an additional 33,710 shares during the period. Pacer Advisors Inc. lifted its holdings in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after purchasing an additional 403,028 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.